Company: MBIO
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001558370-25-003913
Chunk: 0

Company: MUSTANG BIO, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 10
Chunk 0
---
Item 10.     Directors, Executive Officers and Corporate Governance

​

The following table sets forth information regarding our executive officers and directors, including their ages as of the date of this Form 10-K. 

​

Name Age                       Position(s)Executive Officers    Manuel Litchman, M.D. 71 President, Chief Executive Officer, Interim Chief Financial Officer and Director​​​​​Non-Employee Directors    Michael S. Weiss 59 Chairman of the Board of Directors and Executive ChairmanAdam J. Chill 57 DirectorNeil Herskowitz 68 DirectorDavid Jin​35​DirectorLindsay A. Rosenwald, M.D. 69 DirectorMichael J. Zelefsky, M.D. 64 Director

​

Information about our Executive Officers

​

Manuel Litchman, M.D. - President, Chief Executive Officer, Interim Chief Financial Officer and Director

Dr. Litchman has served as our President and Chief Executive Officer, and as a member of our Board since April 2017. He also became Interim Chief Financial Officer in November 2024.  Dr. Litchman joined us from Arvinas, LLC, where he served as President and Chief Executive Officer. While at Arvinas, Dr. Litchman oversaw the advancement of the company’s pipeline of protein-degradation therapeutics for the treatment of cancers and other diseases toward Investigational New Drug applications and secured multi-target discovery collaborations with Merck and Genentech. Prior to Arvinas, Dr. Litchman spent more than 18 years with Novartis Pharmaceuticals Corporation, where he held positions of increasing responsibility related to the development of Novartis’ oncology pipeline. Most recently, Dr. Litchman served as Senior Vice President and Executive Global Program Head, CTL019, Cell & Gene Therapies Unit, where he led a collaboration with the University of Pennsylvania investigating chimeric antigen receptor modified T cells (“CAR Ts”) directed against CD19 on B cell malignancies. Prior to the CTL019 collaboration, Dr. Litchman served as Novartis’ Vice President and Head, Oncology Business Development & Licensing.  Earlier in his career, Dr. Litchman was a senior equity analyst at Ursus Capital and directed oncology/immunology clinical research at Hoffmann-La Roche Inc. Dr. Litchman received his M.D. from Yale University School of Medicine, and